Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

4Total
P 1 (1)
P 2 (2)
P 3 (1)

Trial Status

Recruiting2
Active Not Recruiting1
Not Yet Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials
NCT07723911Phase 3Not Yet RecruitingPrimary

A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL

NCT04629729Phase 1Active Not Recruiting

FT819 in Subjects With B-cell Malignancies

NCT06754267Phase 2RecruitingPrimary

Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL

NCT06742515Phase 2RecruitingPrimary

Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL

Showing all 4 trials

Research Network

Activity Timeline